Dyne Therapeutics, Inc.
Символ: DYN
NASDAQ
25.31
USDПазарна цена днес
-6.6334
Съотношение P/E
0.1185
Коефициент PEG
2.05B
MRK Cap
- 0.00%
Доходност на DIV
Dyne Therapeutics, Inc. (DYN) финансови отчети
Баланс
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 726.87 | 123.1 | 256 | 376.6 | |||||||||||||||||
balance-sheet.row.short-term-investments | 126.24 | 1.5 | 83.9 | 175.7 | |||||||||||||||||
balance-sheet.row.net-receivables | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.other-current-assets | 33.11 | 6.3 | 9.6 | 5.8 | |||||||||||||||||
balance-sheet.row.total-current-assets | 738.58 | 129.4 | 256 | 382.4 | |||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 141.13 | 33.4 | 38.4 | 41 | |||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.long-term-investments | 9.28 | 2.3 | 2.3 | 2.3 | |||||||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.other-non-current-assets | 21.4 | 0 | 9.6 | 0 | |||||||||||||||||
balance-sheet.row.total-non-current-assets | 171.81 | 35.7 | 50.3 | 43.3 | |||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.total-assets | 910.39 | 165.1 | 306.3 | 425.7 | |||||||||||||||||
balance-sheet.row.account-payables | 37.98 | 22.9 | 5.3 | 4 | |||||||||||||||||
balance-sheet.row.short-term-debt | 18.79 | 4.7 | 4.6 | 3.9 | |||||||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.long-term-debt-total | 95.65 | 22.7 | 25.9 | 28.7 | |||||||||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||||||||
balance-sheet.row.other-current-liab | 65.82 | 23.4 | 18.2 | 20.8 | |||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 95.65 | 22.7 | 25.9 | 28.7 | |||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.capital-lease-obligations | 109.72 | 22.7 | 30.5 | 32.6 | |||||||||||||||||
balance-sheet.row.total-liab | 218.25 | 73.8 | 54 | 57.5 | |||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.common-stock | 0.02 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.retained-earnings | -2144.8 | -632.5 | -396.6 | -228.5 | |||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -0.27 | 0 | -0.6 | -0.3 | |||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 2837.19 | 723.8 | 649.5 | 596.9 | |||||||||||||||||
balance-sheet.row.total-stockholders-equity | 692.14 | 91.3 | 252.4 | 368.2 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 910.39 | 165.1 | 306.3 | 425.7 | |||||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.total-equity | 692.14 | 91.3 | 252.4 | 368.2 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 910.39 | - | - | - | |||||||||||||||||
Total Investments | 128.56 | 3.8 | 83.9 | 175.7 | |||||||||||||||||
balance-sheet.row.total-debt | 114.44 | 27.4 | 30.5 | 32.6 | |||||||||||||||||
balance-sheet.row.net-debt | -486.19 | -94.2 | -141.7 | -168.2 |
Отчет за паричните потоци
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -235.94 | -235.9 | -168.1 | -149.3 | |||||||||||||||||
cash-flows.row.depreciation-and-amortization | 1.84 | 2.5 | 1.7 | 1.1 | |||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | -23 | 0 | 2.6 | |||||||||||||||||
cash-flows.row.stock-based-compensation | 19.97 | 20 | 15.2 | 17.5 | |||||||||||||||||
cash-flows.row.change-in-working-capital | 26.31 | 26.3 | -5.4 | 9.3 | |||||||||||||||||
cash-flows.row.account-receivables | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.account-payables | 22.97 | 23 | -1.2 | 13.7 | |||||||||||||||||
cash-flows.row.other-working-capital | 3.34 | 3.3 | -4.1 | -4.4 | |||||||||||||||||
cash-flows.row.other-non-cash-items | -0.34 | 22 | 3 | -0.7 | |||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -188.16 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -0.73 | -0.7 | -3.1 | -3.6 | |||||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.purchases-of-investments | -44.24 | -44.3 | -121.2 | -236.7 | |||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 128.3 | 128.3 | 211.4 | 102.4 | |||||||||||||||||
cash-flows.row.other-investing-activites | -0.02 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 83.31 | 83.3 | 87.2 | -137.9 | |||||||||||||||||
cash-flows.row.debt-repayment | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.common-stock-issued | 52.97 | 54.3 | 36.9 | 157.2 | |||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.other-financing-activites | 1.95 | 2 | 0.5 | 0.6 | |||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 54.32 | 54.3 | 37.4 | 157.8 | |||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.net-change-in-cash | -50.52 | -50.5 | -29.1 | -99.6 | |||||||||||||||||
cash-flows.row.cash-at-end-of-period | 607.6 | 121.6 | 174.5 | 203.5 | |||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 658.11 | 172.1 | 203.5 | 303.2 | |||||||||||||||||
cash-flows.row.operating-cash-flow | -188.16 | -188.2 | -153.6 | -119.6 | |||||||||||||||||
cash-flows.row.capital-expenditure | -0.73 | -0.7 | -3.1 | -3.6 | |||||||||||||||||
cash-flows.row.free-cash-flow | -188.89 | -188.9 | -156.7 | -123.2 |
Ред за отчет за приходите
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 3.79 | 0 | 0 | 0 | |||||||||||||||||
income-statement-row.row.cost-of-revenue | 2.46 | 2.5 | 3.3 | 1.1 | |||||||||||||||||
income-statement-row.row.gross-profit | 1.33 | -2.5 | -3.3 | -1.1 | |||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||
income-statement-row.row.research-development | 210.76 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-general-administrative | 31.4 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | -0.57 | - | - | - | |||||||||||||||||
income-statement-row.row.other-expenses | 2.27 | 0 | 2.9 | 0 | |||||||||||||||||
income-statement-row.row.operating-expenses | 241.59 | 239.7 | 171 | 150 | |||||||||||||||||
income-statement-row.row.cost-and-expenses | 242.16 | 242.2 | 171 | 150 | |||||||||||||||||
income-statement-row.row.interest-income | 7.64 | 7.6 | 2.9 | 0.7 | |||||||||||||||||
income-statement-row.row.interest-expense | 0 | 0 | 2.9 | 0 | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | -0.57 | - | - | - | |||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 4.02 | 6.2 | 2.9 | 0.7 | |||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.other-operating-expenses | 2.27 | 0 | 2.9 | 0 | |||||||||||||||||
income-statement-row.row.total-operating-expenses | 4.02 | 6.2 | 2.9 | 0.7 | |||||||||||||||||
income-statement-row.row.interest-expense | 0 | 0 | 2.9 | 0 | |||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 1.84 | 2.5 | 1.7 | 1.8 | |||||||||||||||||
income-statement-row.row.ebitda-caps | -241.16 | - | - | - | |||||||||||||||||
income-statement-row.row.operating-income | -242.16 | -242.2 | -171 | -150 | |||||||||||||||||
income-statement-row.row.income-before-tax | -235.94 | -235.9 | -168.1 | -149.3 | |||||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 0 | -2.9 | 0 | |||||||||||||||||
income-statement-row.row.net-income | -234.25 | -235.9 | -165.2 | -149.3 |
Често задавани въпроси
Какво е Dyne Therapeutics, Inc. (DYN) общи активи?
Dyne Therapeutics, Inc. (DYN) общите активи са 165082000.000.
Какъв е годишният приход на предприятието?
Годишните приходи са 3788000.000.
Какъв е маржът на печалбата на предприятието?
Маржът на печалбата на фирмата е -3.077.
Какъв е свободният паричен поток на компанията?
Свободният паричен поток е -3.077.
Какъв е маржът на нетната печалба на предприятието?
Маржът на нетната печалба е -61.839.
Какъв е общият приход на предприятието?
Общият приход е -63.928.
Каква е Dyne Therapeutics, Inc. (DYN) нетна печалба (нетен доход)?
Нетната печалба (нетният доход) е -235937000.000.
Какъв е общият дълг на фирмата?
Общият дълг е 27415000.000.
Какъв е броят на оперативните разходи?
Оперативните разходи са 239701000.000.
Какъв е броят на паричните средства на фирмата?
Паричните средства на предприятието са 121626000.000.